GSEA results indicated that numerous typical tumor-related signaling pathways were significantly enriched in ChRCC patients, such as oxidative phosphorylation, PPAR signaling pathway, Notch signaling pathway, P53 signaling pathway, and primary immunodeficiency (Supplementary file Figure 6). This evidence concerns the gene PPARA and inborn error of immunity.